These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 28364582)

  • 1. Clinical relevance of TP53 polymorphic genetic variations in chronic lymphocytic leukemia.
    Bilous N; Abramenko I; Saenko V; Chumak A; Dyagil I; Martina Z; Kryachok I
    Leuk Res; 2017 Jul; 58():1-8. PubMed ID: 28364582
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MDM2 promoter SNP309 is associated with an increased susceptibility to chronic lymphocytic leukemia and correlates with MDM2 mRNA expression in Chinese patients with CLL.
    Dong HJ; Fang C; Fan L; Zhu DX; Wang DM; Zhu HY; Zhuang Y; Miao KR; Liu P; Xu W; Li JY
    Int J Cancer; 2012 May; 130(9):2054-61. PubMed ID: 21647873
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TP53 Gene 72 Arg/Pro (rs1042522) Single Nucleotide Polymorphism Contribute to Increase the Risk of B-Chronic Lymphocytic Leukemia in the Sudanese Population.
    Mohammed Basabaeen AA; Abdelgader EA; Babekir EA; Abdelrahim SO; Eltayeb NH; Altayeb OA; Fadul EA; Sabo A; Ibrahim IK
    Asian Pac J Cancer Prev; 2019 May; 20(5):1579-1585. PubMed ID: 31128065
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TP53 codon 72 single nucleotide polymorphism in chronic lymphocytic leukemia.
    Bilous NI; Abramenko IV; Chumak AA; Dyagil IS; Martіna ZV
    Exp Oncol; 2014 Dec; 36(4):258-61. PubMed ID: 25537220
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Karyotypic complexity rather than chromosome 8 abnormalities aggravates the outcome of chronic lymphocytic leukemia patients with TP53 aberrations.
    Blanco G; Puiggros A; Baliakas P; Athanasiadou A; García-Malo M; Collado R; Xochelli A; Rodríguez-Rivera M; Ortega M; Calasanz MJ; Luño E; Vargas M; Grau J; Martínez-Laperche C; Valiente A; Cervera J; Anagnostopoulos A; Gimeno E; Abella E; Stalika E; Hernández-Rivas JM; Ortuño FJ; Robles D; Ferrer A; Ivars D; González M; Bosch F; Abrisqueta P; Stamatopoulos K; Espinet B
    Oncotarget; 2016 Dec; 7(49):80916-80924. PubMed ID: 27821812
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The distribution of TP53 gene polymorphisms in chronic lymphocytic leukemia patients, sufferers of Chornobyl nuclear power plant accident.
    Bilous NI; Abramenko IV; Chumak AA; Dyagil IS; Martina ZV
    Exp Oncol; 2016 Dec; 38(4):252-256. PubMed ID: 28230820
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of lipoprotein lipase expression with TP53 gene polymorphisms in chronic lymphocytic leukemia cells.
    Abramenko I; Bilous N; Chumak A; Dyagil I; Martina Z
    Exp Oncol; 2021 Sep; 43(3):224-228. PubMed ID: 34591432
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Frequencies of SF3B1, NOTCH1, MYD88, BIRC3 and IGHV mutations and TP53 disruptions in Chinese with chronic lymphocytic leukemia: disparities with Europeans.
    Xia Y; Fan L; Wang L; Gale RP; Wang M; Tian T; Wu W; Yu L; Chen YY; Xu W; Li JY
    Oncotarget; 2015 Mar; 6(7):5426-34. PubMed ID: 25605254
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MDM2 SNP309 is associated with poor outcome in B-cell chronic lymphocytic leukemia.
    Gryshchenko I; Hofbauer S; Stoecher M; Daniel PT; Steurer M; Gaiger A; Eigenberger K; Greil R; Tinhofer I
    J Clin Oncol; 2008 May; 26(14):2252-7. PubMed ID: 18467716
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TP53 polymorphisms in gliomas from Indian patients: Study of codon 72 genotype, rs1642785, rs1800370 and 16 base pair insertion in intron-3.
    Jha P; Jha P; Pathak P; Chosdol K; Suri V; Sharma MC; Kumar G; Singh M; Mahapatra AK; Sarkar C
    Exp Mol Pathol; 2011 Apr; 90(2):167-72. PubMed ID: 21115003
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TP53 mutation and survival in chronic lymphocytic leukemia.
    Zenz T; Eichhorst B; Busch R; Denzel T; Häbe S; Winkler D; Bühler A; Edelmann J; Bergmann M; Hopfinger G; Hensel M; Hallek M; Döhner H; Stilgenbauer S
    J Clin Oncol; 2010 Oct; 28(29):4473-9. PubMed ID: 20697090
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MDM2 SNP309 promoter polymorphism, an independent prognostic factor in chronic lymphocytic leukemia.
    Willander K; Ungerbäck J; Karlsson K; Fredrikson M; Söderkvist P; Linderholm M
    Eur J Haematol; 2010 Sep; 85(3):251-6. PubMed ID: 20491880
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TP53 Pro72 allele potentially increases the poor prognostic significance of TP53 mutation in chronic lymphocytic leukemia.
    Dong HJ; Fang C; Wang L; Fan L; Xu J; Wu JZ; Lu TX; Li JY; Xu W
    Med Oncol; 2014 Apr; 31(4):908. PubMed ID: 24615009
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of TP53 mutations with the AmpliChip p53 research test in chronic lymphocytic leukemia: correlation with clinical outcome and gene expression profiling.
    Chiaretti S; Tavolaro S; Marinelli M; Messina M; Del Giudice I; Mauro FR; Santangelo S; Piciocchi A; Peragine N; Truong S; Patten N; Ghia EM; Torrente I; De Propris MS; Nanni M; Lawrence J; Guarini A; Foà R
    Genes Chromosomes Cancer; 2011 Apr; 50(4):263-74. PubMed ID: 21319261
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between TP53 polymorphisms and chronic lymphocytic leukemia.
    Zhang WJ; Guo SL; Yin G; Wang GS; Wang ZR; Dong J; Li QR
    Eur Rev Med Pharmacol Sci; 2020 Dec; 24(23):12073-12079. PubMed ID: 33336725
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relevance of TP53 for CLL diagnostics.
    Catherwood MA; Gonzalez D; Donaldson D; Clifford R; Mills K; Thornton P
    J Clin Pathol; 2019 May; 72(5):343-346. PubMed ID: 30712002
    [No Abstract]   [Full Text] [Related]  

  • 17. Prognostic significance of ATM and TP53 deletions in Chinese patients with chronic lymphocytic leukemia.
    Xu W; Li JY; Wu YJ; Yu H; Shen QD; Li L; Fan L; Qiu HX
    Leuk Res; 2008 Jul; 32(7):1071-7. PubMed ID: 18035414
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An extensive molecular cytogenetic characterization in high-risk chronic lymphocytic leukemia identifies karyotype aberrations and TP53 disruption as predictors of outcome and chemorefractoriness.
    Rigolin GM; Formigaro L; Cavallari M; Quaglia FM; Lista E; Urso A; Guardalben E; Martinelli S; Saccenti E; Bassi C; Lupini L; Bardi MA; Volta E; Tammiso E; Melandri A; Negrini M; Cavazzini F; Cuneo A
    Oncotarget; 2017 Apr; 8(17):28008-28020. PubMed ID: 28427204
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of a novel regulatory polymorphism (-938C>A) in the BCL2 gene promoter with disease progression and survival in chronic lymphocytic leukemia.
    Nückel H; Frey UH; Bau M; Sellmann L; Stanelle J; Dürig J; Jöckel KH; Dührsen U; Siffert W
    Blood; 2007 Jan; 109(1):290-7. PubMed ID: 16960146
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor Protein 53 Gene Mutations Without 17p13 Deletion Have No Significant Clinical Implications in Chronic Lymphocytic Leukemia. Detection of a New Mutation.
    Diamantopoulos PT; Samara S; Kollia P; Giannakopoulou N; Sofotasiou M; Kalala F; Kodandreopoulou E; Zervakis P; Vassilakopoulos T; Siakantaris M; Mantzourani M; Angelopoulou M; Kyrtshonis MC; Korkolopoulou P; Patsouris E; Viniou NA
    Anticancer Res; 2017 May; 37(5):2387-2391. PubMed ID: 28476805
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.